Telehealth Model for Alzheimer’s Treatment
Synapticure, a leading remote specialty practice focused on neurodegenerative diseases, has unveiled promising data indicating that amyloid-targeted therapies (ATT) can be successfully evaluated and administered via a fully remote telehealth model for patients with early symptomatic Alzheimer's disease. This groundbreaking study will be presented at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference slated for November 19, 2026, in Boston.
Study Overview
The retrospective analysis encompassed 28 patients, treated with either lecanemab (Leqembi®) or donanemab (Kisunla®), across 10 different states. The program operated entirely through Synapticure’s virtual platform, where neurologists provided evaluations and treatment decisions via video consultations. Although the medications require specialized diagnostic evaluations and continuous monitoring, the study revealed that such care can be delivered efficiently and effectively from a distance, removing geographical barriers that often hinder access to care for Alzheimer’s patients.
Remote Specialist Care
What this program demonstrates is how specialist care can be provided remotely. Patients enrolled in the Synapticure program experienced remote monitoring through a dedicated care coordinator who managed their treatment logistics, coordinated local imaging and infusion sites, and followed up on safety protocols. For every MRI that was mandated prior to treatment, the care coordinator ensured that critical checks and necessary preparations were carried out. The results indicated strong compliance with safety protocols, as 100% of the required MRIs were completed prior to the corresponding infusions, with the median time between MRI and infusion being just 9 days.
Key Findings
Upon reviewing the data, several encouraging trends emerged:
- - Diversity of Patient Locations: The 28 patients treated in this study resided in various states, highlighting the reach and capability of the telehealth model.
- - Speed of Treatment: On average, patients received their first infusion just 35 days after their prescription was written. Although delays were sometimes attributed to insurance processes or patient choices, the timeline reflects a significantly expedited experience compared to traditional methods.
- - Monitoring and Safety: The study recorded only 2 cases (7%) of ARIA-E (amyloid-related imaging abnormalities) without any serious adverse events reported. One patient discontinued treatment due to mild ARIA symptoms, reinforcing the effectiveness of the monitoring structure that Synapticure established.
Implications for Alzheimer’s Care
The findings from this research underscore a vital point: access to specialist care does not need to be contingent upon geographic proximity. As highlighted by Dr. Jeremy J. Pruzin, the study’s first author, it is now clear that “a model where living near a specialist is not a requirement” can successfully facilitate access to complex treatments for patients. This shift could be particularly beneficial for individuals living in rural areas with limited access to specialized neurological care.
Furthermore, Sandra Abrevaya, the Chief Executive Officer of Synapticure, expressed optimism regarding the implications of their findings: “Families affected by Alzheimer's shouldn't have to choose between treatment and a long drive or wait for a specialist,” indicating that the growth of tele-neurology could lead to expanded access to vital brain health treatments.
Future Directions
While the initial findings are encouraging, Synapticure acknowledges that this study is based on a small patient cohort. The next steps involve assessing larger populations and extending follow-up periods to validate these promising results further. The implications for Alzheimer's treatment accessibility could be groundbreaking as Synapticure aims to continue scaling its ATT program and reach more patients nationwide.
In summary, this study highlights a transformative potential in how Alzheimer’s care can be administered, reinforcing the significance of specialized oversight in a remote care setting and offering a scalable solution to a pressing healthcare challenge.